Product Information

TOBREX 0.3% EYE OINTMENT is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $84.3333 per GM under NDC 00078081301. Its NADAC has been published 219 times since Sep 7, 2022.

FDA first approved this application before 1982.

The High Outlier badge above means this manufacturer's average price in the tobramycin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

TOBREX 0.3% EYE OINTMENT

tobramycin
$84.3333per GM
High Outlier

Strength

3 mg/g

NDC

00078081301

Classification

Brand

Dosage Form

OINTMENT

Route

OPHTHALMIC

Effective Date

10/21/2026

Active Ingredients

TOBRAMYCIN

Approval Type

New Drug (NDA)

FDA Application

NDA050555

FDA Approved

Before 1982

On Market Since

6/28/1981

Pharmacological Classes

Price Statistics

The NADAC for TOBREX 0.3% EYE OINTMENT has been published 219 times since Sep 7, 2022, and over the history we have for it it has risen 36.9%. The table below summarizes its recorded NADAC range and movement.

Current price$84.3333 per GM
All-time high$84.7026 (Jun 10, 2026)
All-time low$61.5927 (Sep 7, 2022)
52-week high$84.7026
52-week low$76.5414
Median price$70.0225
Average price$73.2252
Largest weekly change+9.9% (Jan 14, 2026)
Weeks tracked219
Tracking sinceSep 7, 2022

Price History

1W

0.0%

1M

-0.1%

3M

-0.2%

6M

+0.2%

1Y

+10.4%

3Y

+24.1%

5Y

N/A

All

+36.9%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the tobramycin market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of TOBREX 0.3% EYE OINTMENT?

The current National Average Drug Acquisition Cost (NADAC) for TOBREX 0.3% EYE OINTMENT, manufactured by Novartis Pharmaceuticals Corporation, is $84.3333 per GM (NDC 00078081301), effective Nov 11, 2026.

How has the price of TOBREX 0.3% EYE OINTMENT changed over time?

Over the history we have for it, the NADAC for TOBREX 0.3% EYE OINTMENT has risen 36.9%. It has been tracked across 219 weekly CMS publications since Sep 7, 2022.

What are the highest and lowest recorded NADAC prices for TOBREX 0.3% EYE OINTMENT?

Since Sep 7, 2022, the NADAC for TOBREX 0.3% EYE OINTMENT has ranged from a low of $61.5927 (Sep 7, 2022) to a high of $84.7026 (Jun 10, 2026), with a median of $70.0225 per GM.

Are there cheaper alternatives to TOBREX 0.3% EYE OINTMENT?

No other NADAC-published product currently shares the active ingredient and strength of TOBREX 0.3% EYE OINTMENT in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures TOBREX 0.3% EYE OINTMENT?

TOBREX 0.3% EYE OINTMENT (NDC 00078081301) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.